ABBVIE (EPA:ABBV) AbbVie Files Form 8-K
Transparency directive : regulatory news
11/05/2016 01:09
Click here to download pdf version
AbbVie Files Form 8-K
NORTH CHICAGO, ILLINOIS, U.S.A., May 6, 2016 - AbbVie Inc. ("AbbVie") (NYSE /
CHX / Euronext Paris / SIX: ABBV) today informs its stockholders that it has
filed a Periodic Report on Form 8-K/A with the U.S. Securities and Exchange
Commission ("SEC") amending the April 25, 2016 announcement regarding the
Agreement and Plan of Merger (the "Merger Agreement") with Stemcentrx, Inc., a
Delaware corporation ("Stemcentrx"), Sirius Sonoma Corporation, a Delaware
corporation and wholly owned subsidiary of AbbVie, Sirius Sonoma LLC, a
Delaware limited liability company and wholly owned subsidiary of AbbVie and,
for certain purposes described in the Merger Agreement, Fertile Valley LLC, a
Delaware limited liability company, pursuant to which Stemcentrx will be
acquired by AbbVie.
AbbVie makes available free of charge on its website, its Annual Report on Form
10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed
pursuant to Section 16 of the U.S. Securities Exchange Act of 1934 and
amendments to those reports filed with or furnished to the SEC as soon as
reasonably practicable after AbbVie electronically files these documents with,
or furnishes them to, the SEC. These documents are posted on AbbVie's website at
www.abbvieinvestor.com.
The SEC maintains a website that contains reports, proxy statements and other
information regarding issuers that file electronically with the SEC. These
materials may be obtained electronically by accessing the SEC's home page at
http://www.sec.gov.
Copies of the above referenced information will also be made available, free of
charge, upon written request to AbbVie Inc., Investors Relations, 1 North
Waukegan Road, North Chicago, Illinois 60064, U.S.A.
Contact: AbbVie Inc., 1-847-938-8745
Document Number: 1233402 Version: 3